A significant advancement in the treatment of rare blood cancers is set to transform the lives of approximately 200 patients…
Read More
Breast cancers that disseminate to bone marrow acquire aggressive phenotypes through CX43-related tumor-stroma tunnels.
A collaborative study conducted by researchers at the University of Michigan and the University of California San Diego has identified…
Read More
Calderasib’s Real Innovation: Designed for Combinability and Potency Unlocks New Frontiers in KRAS-Mutated Cancers
Merck’s latest investigational drug, calderasib, is not merely another entry into the burgeoning field of KRAS G12C inhibition; it represents…
Read More
Breast cancers that disseminate to bone marrow acquire aggressive phenotypes through CX43-related tumor-stroma tunnels
The persistence of estrogen receptor-positive (ER+) breast cancer remains one of the most formidable challenges in modern oncology, as patients…
Read More
Breast cancers that disseminate to bone marrow acquire aggressive phenotypes through CX43-related tumor-stroma tunnels.
This seminal research, conducted by a collaborative team from the University of Michigan and the University of California San Diego,…
Read More
Why tumors resist immunotherapy: how removing their armor can turn cold cancers hot
A groundbreaking study conducted by researchers at the University of California San Diego (CA, USA) has pinpointed microRNA-25 (miR-25) as…
Read More
Breast cancers that disseminate to bone marrow acquire aggressive phenotypes through CX43-related tumor-stroma tunnels.
A collaborative research effort between the University of Michigan and the University of California San Diego has identified a critical…
Read More
Breast cancers that disseminate to bone marrow acquire aggressive phenotypes through CX43-related tumor-stroma tunnels
In a breakthrough study published in the Journal of Clinical Investigation, researchers from the University of Michigan and the University…
Read More
Breast cancers that disseminate to bone marrow acquire aggressive phenotypes through CX43-related tumor-stroma tunnels
Researchers from the University of Michigan and the University of California San Diego have published a groundbreaking study identifying the…
Read More
Merck KGaA and Remepy Forge Groundbreaking Partnership to Pioneer "Hybrid Drugs" for Rare Cancers
In a move that signals a significant shift in pharmaceutical innovation, Merck KGaA has announced a strategic collaboration with Remepy,…
Read MoreYOU MAY HAVE MISSED
